There must be a way to formally balance what can be competing tensions in the form of timely access and affordability. How can we ensure that a focus on affordability is not undermining the goal of timely access, leading to excessive delays and harmful adverse events?
The 'failure to treat' is a major cause of adverse events
September 27, 2021 Latest NewsBioPharmaComment
Latest Video
New Stories
-
If the minister is too embarrassed to respond, it might be the best of bad responses
September 19, 2025 - - Latest News -
Mark Butler acknowledges his concerns over potential impact of US pharmaceutical pricing reforms
September 19, 2025 - - Latest News -
CSL appoints new global head of search to accelerate innovation through strategic partnerships
September 18, 2025 - - Latest News -
Pharmacy Guild of Australia acquires Member Benefits Australia
September 18, 2025 - - Latest News -
Sanofi promotes a national dialogue on health literacy and trust
September 18, 2025 - - Latest News -
Island Pharmaceuticals reports breakthrough survival data for galidesivir in Marburg and Ebola studies
September 17, 2025 - - Australian Biotech -
Australian Dementia Network Registry wants access to 'turning point' therapies
September 17, 2025 - - Latest News